HC Wainwright & Co. Maintains Buy on Surrozen, Raises Price Target to $54

Surrozen, Inc. Schedules Third Quarter 2026 Earnings Announcement

Surrozen, Inc. has scheduled the release of its financial results for the third quarter of 2026 for November 11, 2026.

Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million

Surrozen, Inc. (NASDAQ: SRZN) announced the closing of its second tranche of a private placement, raising approximately $95.1 million in gross proceeds. The closing was triggered by FDA clearance of the IND application for SZN-8141 on October 2, 2026. The company now has cash runway into 2029 to advance its ophthalmology pipeline, including the DUET Phase 1b/2a study of SZN-8141 for diabetic macular edema and initial clinical development of SZN-8143. First patient dosing in the DUET study is expected in Q4 2026, with initial data anticipated in H2 2027.

8-K filing — Surrozen, Inc./DE (SRZN)

Filed: 2026-10-20 AccNo: 0001193125-26-426828 Size: 199 KB Item 2.02: Results of Operations and Financial Condition Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

Surrozen Says FDA Cleared IND For SZN-8141 In Diabetic Macular Edema, Triggering About $95.1M Second Tranche Of Private Placement

Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

U.S. stock futures rose, but Scholastic plunged 9.9% after missing Q1 loss and sales estimates; several other stocks also fell premarket.

Why INLIF Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket

INLIF shares jumped 78% after H1 FY26 revenue rose 26%, gross profit surged 159% and net income turned positive; other premarket movers varied.